Nicotrol effectiveness in controlling "worst cravings" is substantiated, J&J tells NAD.
This article was originally published in The Tan Sheet
Executive Summary
NICOTROL EFFECTIVENESS IN CONTROLLING "WORST CRAVINGS" is demonstrated in the two large clinical trials submitted to FDA in support of the Rx-to-OTC switch application for the smoking cessation patch, McNeil parent Johnson & Johnson maintains in an April 15 letter to the National Advertising Division of the Council of Better Business Bureaus.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning